IL251103A0 - Histone demethylase inhibitors - Google Patents
Histone demethylase inhibitorsInfo
- Publication number
- IL251103A0 IL251103A0 IL251103A IL25110317A IL251103A0 IL 251103 A0 IL251103 A0 IL 251103A0 IL 251103 A IL251103 A IL 251103A IL 25110317 A IL25110317 A IL 25110317A IL 251103 A0 IL251103 A0 IL 251103A0
- Authority
- IL
- Israel
- Prior art keywords
- histone demethylase
- demethylase inhibitors
- inhibitors
- histone
- demethylase
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051268P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/050289 WO2016044342A1 (en) | 2014-09-16 | 2015-09-15 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL251103A0 true IL251103A0 (en) | 2017-04-30 |
Family
ID=55533770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251103A IL251103A0 (en) | 2014-09-16 | 2017-03-12 | Histone demethylase inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9676770B2 (enExample) |
| EP (1) | EP3193881B1 (enExample) |
| JP (1) | JP6660060B2 (enExample) |
| KR (1) | KR20170048590A (enExample) |
| CN (1) | CN107073006A (enExample) |
| AU (1) | AU2015317904A1 (enExample) |
| BR (1) | BR112017005128A2 (enExample) |
| CA (1) | CA2961525A1 (enExample) |
| CL (1) | CL2017000643A1 (enExample) |
| CO (1) | CO2017002772A2 (enExample) |
| EA (1) | EA201790502A1 (enExample) |
| EC (1) | ECSP17020172A (enExample) |
| ES (1) | ES2911292T3 (enExample) |
| IL (1) | IL251103A0 (enExample) |
| MX (1) | MX2017003464A (enExample) |
| SG (1) | SG11201702108PA (enExample) |
| WO (1) | WO2016044342A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731773T3 (es) | 2013-03-14 | 2019-11-19 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MX2017003464A (es) * | 2014-09-16 | 2017-07-13 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa. |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| SI3371190T1 (sl) | 2015-11-06 | 2022-08-31 | Incyte Corporation | Heterociklične spojine kot inhibitorji PI3K gama |
| WO2017120194A1 (en) * | 2016-01-05 | 2017-07-13 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
| WO2017161033A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| SI3697789T1 (sl) | 2017-10-18 | 2022-04-29 | Incyte Corporation | Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN111116571B (zh) * | 2019-12-27 | 2022-07-12 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| MXPA03003599A (es) | 2000-10-26 | 2003-08-01 | Tularik Inc | Agentes antiinflamatorios. |
| GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2632444A1 (en) | 2005-12-19 | 2007-06-28 | Boehringer Ingelheim International Gmbh | Use of aminoalcohol derivatives for the treatment of overactive bladder |
| CA2701124A1 (en) | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| CA2778886C (en) | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP3763367A1 (en) * | 2012-12-06 | 2021-01-13 | Celgene Quanticel Research, Inc. | Pyridine-pyrazole derivatives as histone demethylase inhibitors |
| ES2731773T3 (es) * | 2013-03-14 | 2019-11-19 | Celgene Quanticel Res Inc | Inhibidores de la histona desmetilasa |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9896436B2 (en) * | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MX2017003464A (es) | 2014-09-16 | 2017-07-13 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa. |
-
2015
- 2015-09-15 MX MX2017003464A patent/MX2017003464A/es unknown
- 2015-09-15 SG SG11201702108PA patent/SG11201702108PA/en unknown
- 2015-09-15 EP EP15842092.7A patent/EP3193881B1/en not_active Not-in-force
- 2015-09-15 BR BR112017005128A patent/BR112017005128A2/pt not_active Application Discontinuation
- 2015-09-15 CA CA2961525A patent/CA2961525A1/en not_active Abandoned
- 2015-09-15 KR KR1020177009901A patent/KR20170048590A/ko not_active Withdrawn
- 2015-09-15 ES ES15842092T patent/ES2911292T3/es active Active
- 2015-09-15 CN CN201580060763.8A patent/CN107073006A/zh active Pending
- 2015-09-15 JP JP2017514411A patent/JP6660060B2/ja not_active Expired - Fee Related
- 2015-09-15 WO PCT/US2015/050289 patent/WO2016044342A1/en not_active Ceased
- 2015-09-15 US US14/855,269 patent/US9676770B2/en active Active
- 2015-09-15 AU AU2015317904A patent/AU2015317904A1/en not_active Abandoned
- 2015-09-15 EA EA201790502A patent/EA201790502A1/ru unknown
-
2017
- 2017-03-12 IL IL251103A patent/IL251103A0/en unknown
- 2017-03-16 CL CL2017000643A patent/CL2017000643A1/es unknown
- 2017-03-23 CO CONC2017/0002772A patent/CO2017002772A2/es unknown
- 2017-03-31 EC ECIEPI201720172A patent/ECSP17020172A/es unknown
- 2017-05-05 US US15/588,495 patent/US10071984B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6660060B2 (ja) | 2020-03-04 |
| AU2015317904A1 (en) | 2017-04-06 |
| EP3193881A1 (en) | 2017-07-26 |
| EP3193881A4 (en) | 2018-02-21 |
| EA201790502A1 (ru) | 2017-10-31 |
| KR20170048590A (ko) | 2017-05-08 |
| US20160108033A1 (en) | 2016-04-21 |
| SG11201702108PA (en) | 2017-04-27 |
| WO2016044342A1 (en) | 2016-03-24 |
| CO2017002772A2 (es) | 2017-06-09 |
| US10071984B2 (en) | 2018-09-11 |
| BR112017005128A2 (pt) | 2018-07-31 |
| US9676770B2 (en) | 2017-06-13 |
| CL2017000643A1 (es) | 2017-12-01 |
| US20170240529A1 (en) | 2017-08-24 |
| JP2017527590A (ja) | 2017-09-21 |
| EP3193881B1 (en) | 2022-02-09 |
| ES2911292T3 (es) | 2022-05-18 |
| ECSP17020172A (es) | 2017-05-31 |
| CN107073006A (zh) | 2017-08-18 |
| CA2961525A1 (en) | 2016-03-24 |
| MX2017003464A (es) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL249629A0 (en) | Histone demethylase inhibitors | |
| IL249281A0 (en) | Cyclopropylamine compounds as histone demethylase inhibitors | |
| IL250355A0 (en) | Compounds and methods for inhibiting histone demethylases | |
| IL246362A0 (en) | Novel glutaminase inhibitors | |
| PL2970211T3 (pl) | Inhibitory demetylazy histonowej | |
| GB201421083D0 (en) | Enzyme inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| GB201421088D0 (en) | New enzyme inhibitors | |
| BR112017000043A2 (pt) | inibidores da desmetilase específica de lisina-1 | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| IL251103A0 (en) | Histone demethylase inhibitors | |
| IL251179A0 (en) | Histone demethylase inhibitors | |
| GB201421085D0 (en) | New enzyme inhibitors | |
| GB201612860D0 (en) | Inhibitors | |
| IL256438B (en) | Histone deacetylase inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| GB201400299D0 (en) | Corrosion inhibitors | |
| IL251184A0 (en) | Histone demethylase inhibitors | |
| GB201520949D0 (en) | Inhibitors | |
| HK1233859A1 (en) | Histone demethylase inhibitors | |
| HK1233942A1 (zh) | 组蛋白去甲基化酶抑制剂 | |
| HK1234046A1 (en) | Histone demethylase inhibitors | |
| GB201418154D0 (en) | Inhibitors | |
| GB201400300D0 (en) | Corrosion inhibitors |